BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31576199)

  • 1. Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience.
    Almahari SA; Harb Z; Alshaikh S
    Cytojournal; 2019; 16():18. PubMed ID: 31576199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
    Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinico-cytopathological subcategorization in thyroid nodules of atypia of undetermined significance/follicular lesion of undetermined significance using the TIRADS and Bethesda classifications.
    Babajani A; Rahmani S; Raoufi M; Eidgahi ES; Dastjerdi AV; Behfarnia P; Khalili S; Moghaddam NA
    Front Endocrinol (Lausanne); 2023; 14():1135196. PubMed ID: 37313444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
    Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
    Ann Otol Rhinol Laryngol; 2017 Sep; 126(9):625-633. PubMed ID: 28719972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid fine-needle aspirations: A six-year institutional experience.
    Xu XM; Angelova E; Clement CG
    Diagn Cytopathol; 2021 Aug; 49(8):915-920. PubMed ID: 33973739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategy to reduce unnecessary surgeries in thyroid nodules with cytology of Bethesda category III (AUS/FLUS): a retrospective analysis of 667 patients diagnosed by surgery.
    Suh YJ; Choi YJ
    Endocrine; 2020 Sep; 69(3):578-586. PubMed ID: 32297204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Mulita F; Plachouri MK; Liolis E; Vailas M; Panagopoulos K; Maroulis I
    Endokrynol Pol; 2021; 72(2):143-144. PubMed ID: 33749812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of repeat fine-needle aspiration in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance: A single center experience.
    Marin F; Murillo R; Diego C; Jodar E; Acevedo A
    Diagn Cytopathol; 2021 Mar; 49(3):412-417. PubMed ID: 33252841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology.
    Topaloglu O; Baser H; Cuhaci FN; Sungu N; Yalcin A; Ersoy R; Cakir B
    Endocrine; 2016 Oct; 54(1):156-168. PubMed ID: 27172917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
    Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
    Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
    Rosario PW
    Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy.
    Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY
    Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
    Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
    Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of thyroid nodules classified as Bethesda category III on FNAC.
    Garg S; Naik LP; Kothari KS; Fernandes GC; Agnihotri MA; Gokhale JC
    J Cytol; 2017; 34(1):5-9. PubMed ID: 28182068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.
    Al Dawish M; Alwin Robert A; Al Shehri K; Hawsawi S; Mujammami M; Al Basha IA; Alrasheed M; Asiri S; Alzouman M; Alkharashi E
    Cureus; 2020 May; 12(5):e8202. PubMed ID: 32455091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of atypia/follicular lesion of undetermined significance: An institutional experience.
    Wong LQ; LiVolsi VA; Baloch ZW
    Cytojournal; 2014; 11():23. PubMed ID: 25210530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.